Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases
Abstract This study investigates the effects of bevacizumab, a common vascular endothelial growth factor (VEGF) inhibitor, in treating ocular neovascular disorders, with a focus on its impact on retinal ganglion cell (RGC) survival. Given that bevacizumab has been associated with adverse effects on...
Saved in:
| Main Authors: | Wungrak Choi, Jin-Ok Choi, Min Kyung Chae, Min Seok Kim, Chan Yun Kim |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-12199-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glaucomatous retinal ganglion cells: death and protection
by: Na Cui, et al.
Published: (2025-01-01) -
Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma
by: Nisha Rajakrishna, et al.
Published: (2025-04-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
Glial and immune dysregulation in glaucoma independent of retinal ganglion cell loss: a human post-mortem histopathology study
by: Akanksha Salkar, et al.
Published: (2025-06-01) -
Retinal Vessel Diameter Reductions Are Associated with Retinal Ganglion Cell Dysfunction, Thinning of the Ganglion Cell and Inner Plexiform Layers, and Decreased Visual Field Global Indices in Glaucoma Suspects
by: Andrew Tirsi, et al.
Published: (2025-07-01)